NABP Tackles Unseen Risks with New Compounding Safety Clearinghouse

MOUNT PROSPECT, Ill. – July 29, 2026 – In a significant move to enhance patient safety, the National Association of Boards of Pharmacy® (NABP®) has announced a major initiative to develop a national adverse event reporting clearinghouse for compounded medications. The new system is designed to capture and centralize reports of patient harm, creating a vital information-sharing network between state boards of pharmacy and the US Food and Drug Administration (FDA).

This initiative directly confronts a longstanding and critical vulnerability in the nation's drug safety infrastructure. While large-scale drug manufacturers and 503B outsourcing facilities are federally mandated to report adverse events, the vast network of 503A compounding pharmacies—which prepare customized medications for individual patients—operates without such a requirement. This regulatory gap means that when a patient is harmed by a medication from a local compounding pharmacy, the incident may never be formally recorded or shared beyond state lines, leaving other patients and regulators in the dark.

“When a patient is harmed by a compounded medication, that information too often stays in one state, or never surfaces at all,” said Lemrey “Al” Carter, PharmD, MS, RPh, executive director of NABP. “We cannot protect patients from risks regulators cannot see. A national clearinghouse would let the boards of pharmacy and FDA share what each of them learns, so that a harm detected in one state can protect patients in every other state. This is the type of project that NABP is uniquely positioned to conduct and, working with our member boards and the FDA, we intend to champion it.”

A Critical Blind Spot in Patient Safety

The current regulatory landscape for compounded drugs is split into two distinct categories. Section 503B of the Federal Food, Drug, and Cosmetic Act governs large “outsourcing facilities” that produce sterile drugs in bulk and are subject to stringent FDA oversight, including mandatory adverse event reporting. In contrast, 503A pharmacies are traditional pharmacies primarily regulated by state boards. They compound drugs based on individual prescriptions, a practice essential for patients who need specific formulations, dosages, or allergen-free medications not available commercially.

However, this state-led oversight model creates a national blind spot. Without a federal requirement or a centralized system for 503A pharmacies to report adverse events, regulators lack a comprehensive view of the risks associated with these preparations. The problem has become more acute with the recent surge in demand for certain compounded medications, such as GLP-1 agonists for weight loss and diabetes, which has pushed compounding volumes far beyond the small-scale model the current framework was designed to support.

The potential consequences of this information gap are severe. The 2012 fungal meningitis outbreak, linked to a compounding pharmacy in New England, resulted in over 750 illnesses and more than 70 deaths, serving as a tragic reminder of what can happen when quality control fails. While that incident led to the creation of the 503B category, the fundamental reporting gap for 503A pharmacies has persisted. NABP’s initiative aims to finally close this loophole, ensuring that safety signals—no matter how small or isolated—are collected, analyzed, and acted upon.

Unifying Oversight Across State and Federal Lines

NABP's proposed clearinghouse is more than just a database; it is a foundational tool for modernizing and unifying regulatory oversight. Currently, an adverse event in one state may be investigated by the local board of pharmacy, but there is no streamlined mechanism to alert regulators in other states who may be overseeing pharmacies using the same bulk ingredients or compounding practices. The FDA, which lacks the statutory authority to mandate reporting from 503A pharmacies, also misses out on this crucial data.

The clearinghouse will function as a central nervous system for compounding safety, connecting the disparate state boards and the FDA. This aligns with a growing consensus among policymakers that action is needed. Recent legislative proposals, such as the SAFE Drugs Act of 2026, also seek to mandate serious adverse event reporting from 503A pharmacies, underscoring the urgency and importance of the issue NABP is tackling.

This initiative is the cornerstone of a broader, coordinated patient-safety strategy by the Association and its member boards. In addition to the clearinghouse, NABP intends to pursue several other critical measures. These include working with the FDA to expand real-time information sharing under existing legal authorities, developing model standards to help pharmacies verify the quality of bulk drug substances used in compounding, and building coordinated referral pathways among state pharmacy boards, medical boards, and attorneys general to handle complex cases that cross jurisdictional lines. Together, these efforts represent a comprehensive approach to strengthening the entire compounding ecosystem.

Reshaping the Compounding Industry for the Better

The introduction of a national reporting system is poised to have a transformative impact on the compounding industry itself, driving a new era of transparency and accountability. For thousands of 503A pharmacies, this will necessitate enhanced internal processes for monitoring, documenting, and reporting patient outcomes. While this represents a new administrative responsibility, it also provides an opportunity for high-quality pharmacies to demonstrate their commitment to patient safety.

“This will fundamentally raise the bar for everyone,” noted one state board of pharmacy official who spoke on the condition of anonymity. “It will help us identify patterns we can’t currently see and allow responsible pharmacies to differentiate themselves based on their safety record.”

By collecting and analyzing data on a national scale, the clearinghouse will enable regulators to identify trends related to specific drugs, ingredients, or compounding techniques that pose a risk. This data-driven approach could lead to more targeted inspections, updated practice standards, and better guidance for the entire industry. It promises to reward pharmacies that invest in robust quality control while making it more difficult for those with substandard practices to operate undetected.

Recognizing the challenges of implementation, NABP plans to convene a wide range of stakeholders—including boards of pharmacy, FDA officials, and compounding industry representatives—in the coming months. This collaborative process will define the clearinghouse's design, governance, and technical specifications, ensuring the final system is both effective for regulators and practical for pharmacists. Key considerations will include establishing a user-friendly reporting interface, defining clear and consistent terms for what constitutes a reportable event, and fostering a non-punitive environment that encourages reporting as a tool for continuous quality improvement.

By bringing all parties to the table, NABP aims to build a system founded on shared responsibility for patient health. The ultimate goal is to strengthen the integrity of compounded medications, ensuring that patients and prescribers can have confidence in the safety and quality of these essential treatments.